Rib-X Pharmaceutical makes board appointment
This article was originally published in Scrip
Rib-X Pharmaceuticals, a US development-stage company focused on the discovery and development of antibiotics for the treatment of antibiotic-resistant infections, has elected Dr Russell Greig to its board of directors. The appointment brings the total number of board members to 11. Dr Greig is president of SR One, the venture capital arm of GlaxoSmithKline. Before that, he served as president of GSK's Pharmaceuticals International from 2003-08.